Specialty pharmaceutical company selling gastrointestinal, dermatology, neurology and international generics products.
Specialty pharmaceutical company selling gastrointestinal, dermatology, neurology and international generics products.
Revenue comes mainly from branded prescription drugs and medical devices, where patents and regulatory exclusivity allow firm pricing, plus the eye-care business Bausch + Lomb, which it listed in 2022 while keeping control. Heavy debt left from the Valeant-era acquisition spree means a large share of cash flow goes to servicing and refinancing it.
Moat: narrow (IP / patents, distribution). Xifaxan and other branded drugs have patent/exclusivity protection and established prescriber relationships.
Headquarters: Laval, Canada · Employees: 20,300
Size Bausch Health Companies (BHC.TO) is a Canada Health Care company (Pharmaceuticals: Other) with a market value of $3.27B, the 147th largest of 405 Canada companies the cockpit tracks. Shares closed at C$12.52 on 18 Nov 2026.
Performance Over six months the shares gained 65.6%, against -1.6% for the median peer and +1.1% for the Canada market (cap-weighted) — 3rd highest of 21 in its peer set.
Growth Revenue grew 10.1% over the last twelve months (peer median +8.1%); the operating margin is 27.2% (peer median 14.3%).
Valuation It trades at 2.0× forward earnings against a peer median of 17.8× (cheapest of 16).
Price implies For today's price to make sense, revenue must grow about -15% a year for seven years (Req g). Recent delivered growth is +6%, so the hurdle is -21 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 6.5 points above its cost of capital (5.0% WACC).
Next results Next results expected around 24 Feb 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | C$15.4B | C$14.3B | C$13.2B | C$11.8B | C$10.6B |
| Revenue growth | — | +9% | +12% | +12% | — |
| Gross profit | C$9.91B | C$8.74B | C$7.90B | C$6.91B | C$5.92B |
| EBITDA | C$5.79B | C$4.74B | C$4.28B | C$3.87B | C$3.63B |
| Net income | -C$1.14B | C$219M | -C$63.0M | -C$799M | -C$293M |
| Free cash flow | C$2.58B | C$1.34B | C$1.72B | C$1.05B | -C$1.32B |
| Capital expenditure | C$530M | C$569M | C$466M | C$367M | C$349M |
| Total debt | C$29.4B | C$28.9B | C$31.4B | C$29.8B | C$28.5B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Bausch Health Companies BHC.TO | $3.27B | +66% | +10% | 27% | 2.0× | -14.8% |
| Bausch + Lomb BLCO.TO | $7.41B | +35% | +11% | 9% | 18.3× | 12.0% |
| Organon & OGN | $3.66B | +3% | -3% | 20% | 4.0× | -4.1% |
| Viatris VTRS | $23.3B | +23% | +5% | 11% | 7.5× | 11.2% |
| Galderma GALD.SW | $51.9B | +18% | +16% | 19% | 45.7× | 18.0% |
| Takeda Pharmaceutical 4502.T | $69.8B | +30% | +6% | 18% | 51.0× | 3.7% |
| Sun Pharmaceutical Industries SUNPHARMA.NS | $48.0B | -1% | +12% | 23% | 36.0× | 28.7% |
| Teva Pharmaceutical Industries Limited Sponsored ADR TEVA | $49.3B | +23% | -4% | 19% | 15.0× | 10.5% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | BHC.TO | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +39.0% | -1.3% | highest of 21 |
| 6-month return | +65.6% | -1.6% | 3rd highest of 21 |
| Distance from 52-week high | -1.1% | -23.4% | 2nd highest of 21 |
| Revenue growth (TTM) | +10.1% | +8.1% | 10th highest of 20 |
| Operating margin | 27.2% | 14.3% | 5th highest of 20 |
| Forward P/E | 2.0× | 17.8× | cheapest of 16 |
| Growth the price implies (Req g, 7 yrs) | -14.8% | 1.8% | least demanding of 19 |
| Growth delivered (Del g) | +5.9% | +8.1% | 9th lowest of 19 |
| Hurdle (Req g minus delivered) | -20.7 pp | -7.0 pp | 2nd least demanding of 19 |
| ROIC minus cost of capital | +6.5 pp | +2.6 pp | 8th highest of 20 |
| EV / EBITDA | 5.5× | 18.1× | cheapest of 9 |
| Net debt / EBITDA | 4.5× | 0.0× | 2nd most indebted of 9 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Bausch Health Companies BHC.TO | Canada | $3.27B | +66% | +10% | 27% | 2.0× | -14.8% | +5.9% |
| Guangdong Zhongsheng Pharmaceutical 002317.SZ | China | $3.00B | +11% | -14% | 9% | 91.7× | 33.8% | +5.9% |
| Jilin Aodong Pharmaceutical 000623.SZ | China | $2.97B | -7% | -4% | -13% | n/a | 5.0% | +1.0% |
| Shijiazhuang Yiling Pharmaceutical 002603.SZ | China | $3.83B | -7% | +32% | 21% | 17.5× | -3.9% | -2.2% |
| By-health 300146.SZ | China | $2.56B | -1% | +10% | 11% | 24.7× | 4.8% | +0.6% |
| China Resources Double-Crane Pharmaceutical 600062.SS | China | $2.35B | -14% | -1% | 13% | 9.3× | -9.1% | +5.3% |
| China Resources Jiangzhong Pharmaceutical 600750.SS | China | $2.27B | +4% | -10% | 24% | 16.5× | -1.9% | +11.6% |
| Health and Happiness (H&H) International 1112.HK | Hong Kong | $2.15B | +108% | +24% | 16% | 13.2× | -1.7% | +4.4% |
| Dong-E-E-Jiao 000423.SZ | China | $4.99B | +1% | +8% | 29% | 17.8× | -3.7% | +14.5% |
| Granules India GRANULES.NS | India | $2.12B | +4% | +22% | 17% | 24.8× | 23.6% | +10.6% |
| China Meheco 600056.SS | China | $1.90B | -16% | +2% | 3% | n/a | -1.3% | -2.1% |
| Porton Pharma Solutions 300363.SZ | China | $1.66B | +37% | +6% | -2% | n/a | 2.1% | +10.4% |
| Tibet Cheezheng Tibetan Medicine 002287.SZ | China | $1.58B | -17% | -7% | 28% | n/a | -1.9% | +10.4% |
| Zhejiang Medicine 600216.SS | China | $1.51B | -26% | -6% | 7% | 11.5× | -7.8% | +3.9% |
| Sudeep Pharma SUDEEPPHRM.NS | India | $1.45B | +85% | +27% | 33% | 69.1× | n/a | n/a |
| Abivax ABVX.PA | France | $7.36B | -30% | n/a | n/a | n/a | n/a | n/a |
| Jamieson Wellness JWEL.TO | Canada | $1.32B | +32% | +12% | 13% | 20.6× | 13.5% | +15.3% |
| Bora Pharmaceuticals 6472.TW | Taiwan | $1.25B | -2% | +7% | 14% | 10.8× | 3.5% | +60.2% |
| BioGaia BIOG-B.ST | Sweden | $1.25B | -4% | +13% | 28% | 31.0× | 1.5% | +15.5% |
| Pharma Mar PHM.MC | Spain | $1.21B | -38% | +32% | 19% | 41.4× | 10.6% | -3.9% |
| Cronos CRON.TO | Canada | $1.17B | +24% | +55% | 5% | 16.2× | 18.8% | +26.7% |